Other Events. On August 6, 2026, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2025 and was declared effective by the SEC on May 27, 2025 (the “Registration Statement”), relating to the offer and sale of a total of up to $200.0 million of shares of the Compa…

Director — Ilan Ganot: Mr. Ilan Ganot's reassignment from Class III to Class I of the Board of Directors for balance purposes.

Other Events. SGT-003 Interim Clinical Update for INSPIRE DUCHENNE On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy (“Duchenne”) at a dose level of 1E14vg/kg. SGT-003 is administered as a one-time intravenous infusion. The inte…

Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Shares and the Pre-Funded Warrants will be exempt from registration under Section 4(a)(2) of the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per shar…

Results of Operations and Financial Condition. Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company expects to report cash, cash equivalents and available-for-sale securities of approximately $187.9 million as of December 31, 2025. The estimated cash, cash equivalents and available-for-sale securities figure is preliminary and unaudited, represents management’s estimate as of the date of this report, is s…

Other Events. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the Private Placement, together with the Company’s existing cash, cash equivalents and available-for-sale securities, will enable the Company to fund its operating expenses and capital expenditure requirements into the first half of 2028. The Company expects to use the net proceeds from the Private Placement, together with its existing cash, cash equivalents and available-for-sale s…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events. On May 15, 2025, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-277871) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2024 and was declared effective by the SEC on May 17, 2024 (the “Registration Statement”), relating to the offer and sale of a total of up to $85.0 million of shares of the Compan…

Entry Into a Material Definitive Agreement. On February 18, 2025, Solid Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 35,739,810 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Comm…

Other Events. On February 18, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, such as those, among others, relating to the expecte…

Other Events. On February 18, 2025, Solid Biosciences Inc. (the “Company”) issued a press release announcing the pricing of a $200.0 million underwritten offering, which is expected to close on February 19, 2025. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and available-for-sale securities, will enable the Company to fund its operating expenses and capital expenditur…

Results of Operations and Financial Condition. The information disclosed under the heading “Cash, Cash Equivalents and Available-for-Sale Securities as of December 31, 2024” under

Other Events. On January 8, 2024, the Company issued a press release announcing the Private Placement. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. On January 8, 2024, the Company announced that it anticipates providing an initial safety update from cohort 1 of its Phase 1/2 clinical trial, SGT-003-101, a first in human, open-label, multicenter trial to determ…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On January 8, 2024, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 16,973,103 shares of the Company’s common stock, par value $0.001 per sh…

Results of Operations and Financial Condition. Spokespersons of the Company plan to present the information in the presentation attached hereto as Exhibit 99.1 (the “ Presentation ”) at various meetings beginning on January 8, 2024, including investor and analyst meetings in connection with the J.P. Morgan Healthcare Conference. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Although the Company has not finali…

Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Shares and the Pre-Funded Warrants will be exempt from registration under Section 4(a)(2) of the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption…

Chief Scientific Officer, Neuromuscular — Carl Morris: Dr. Carl Morris resigned as Chief Scientific Officer, Neuromuscular with a transition plan and severance package.

Chief Financial Officer — Kevin Tan: Kevin Tan was appointed as the Chief Financial Officer, replacing Stephen DiPalma.

Results of Operations and Financial Condition. Spokespersons of Solid Biosciences Inc. (the “Company”) plan to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at various meetings beginning on January 9, 2023, including investor and analyst meetings in connection with the J.P. Morgan Healthcare Conference. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Although t…

Costs Associated with Exit or Disposal Activities. On November 30, 2022, the Company’s Board of Directors (the “Board”) approved a plan to reduce the Company’s workforce by approximately 18%. These reductions are expected to be completed by the December 5, 2022. This plan is designed to streamline the Company’s operating structure. The Company expects to incur a charge in the fourth quarter of 2022 of approximately $3.2 million related to the reduction in force, consisting of severance and ot…

Completion of Acquisition or Disposition of Assets. As previously disclosed, on September 29, 2022, the Company, Transitory Subsidiary, AavantiBio and Doug Swirsky, acting solely in his capacity as equityholder representative, entered into the Merger Agreement. On December 2, 2022, the Company completed its acquisition of AavantiBio in accordance with the terms of the Merger Agreement. At the closing of the Acquisition, the Company issued an aggregate of (i) $1,000 and (ii) 1,354,258 shares o…

President and Chief Executive Officer — Alexander (Bo) Cumbo: Mr. Cumbo was appointed as the President and Chief Executive Officer, subject to the closing of an acquisition.

On September 29, 2022, the Company entered into the Securities Purchase Agreement with the PIPE Investors, pursuant to which, on December 2, 2022, the Company issued an aggregate of 10,638,290 shares of the Company’s common stock (the “PIPE Shares”). The Private Placement closed immediately following the closing of the Acquisition on December 2, 2022. The Company received aggregate gross proceeds from the Private Placement of approximately $75.0 million, before deducting placement agent fees…

Entry into a Material Definitive Agreement. As a result of the Acquisition, the following AavantiBio agreements and arrangements effectively became agreements and arrangements of the Company. License Agreements with the University of Florida Research Foundation, Inc. Between March 2020 and June 2021, AavantiBio entered into multiple license agreements with the University of Florida Research Foundation, Inc. (the “UFRF License Agreements”). Broadly, the license agreements grant rights to certa…